GO
Loading...

Pharmaceuticals

More

  • *Intel capital expenditure cut hits chip-related shares. *Obayashi gains after raising earnings outlook. TOKYO, April 15- Japan's Nikkei share average was flat on Wednesday as investors took profits on recent gainers such as drugmakers, but expectations that companies will report strong profits supported sentiment.

  • UPDATE 1-Aduro IPO pricing values drugmaker at $1 bln Tuesday, 14 Apr 2015 | 6:23 PM ET

    Aduro, which counts Johnson& Johnson and Swiss drugmaker Novartis AG among its investors, is selling all the 7 million shares in the offering. To gain access to Aduro's cancer immunotherapy technology, Novartis last month entered into a tie-up worth about $750 million with the company. Novartis Institutes for BioMedical Research Inc, an affiliate of Novartis,...

  • IBM takes medical data to the cloud   Tuesday, 14 Apr 2015 | 10:39 AM ET
    IBM takes medical data to the cloud

    Mike Rhodin, IBM Watson, weighs in on the future of IBM's Watson Health Cloud

  • J&J earnings beat despite THIS factor Tuesday, 14 Apr 2015 | 9:25 AM ET
    Johnson & Johnson gauze pads

    Johnson & Johnson reports quarterly earnings that beat expectations despite a 7.2 percent drag on the strong dollar.

  • Johnson & Johnson beats Street 1Q forecasts Tuesday, 14 Apr 2015 | 7:54 AM ET

    Johnson& Johnson's first-quarter profit uncharacteristically fell 8.6 percent, hurt by sharply unfavorable exchange rates, a major divestiture and competition to its new hepatitis C drug. However, Johnson& Johnson reduced its full-year profit forecast, saying it now expects earnings of $6.04 to $6.19 per share, down from $6.12 to $6.27.

  • Drug spending increases   Tuesday, 14 Apr 2015 | 7:00 AM ET
    Drug spending increases

    CNBC's Landon Dowdy on the rise of spending on prescription drugs.

  • April 13- Drugmaker Mylan N.V said it settled a patent litigation with Pfizer Inc related to Viagra, paving the way for the launch of the drug's generic version in the United States once approved. Pfizer's patent for Viagra, used to treat erectile dysfunction, expires in 2020.. Pfizer's shares closed down marginally at $35.09, after touching an 11- year high on...

  • Mylan settles Viagra patent litigation with Pfizer Monday, 13 Apr 2015 | 3:33 PM ET

    April 13- Drugmaker Mylan N.V said it settled a patent litigation with Pfizer Inc related to the generic version of Viagra. Mylan said the settlement would allow it to launch a generic version of the drug as early as December 2017, or sooner under certain conditions, subject to approval by U.S. health regulators. Other terms of the settlement were not disclosed.

  • NEW YORK, April 13- Actavis Plc urged a U.S. appeals court on Monday to allow it to discontinue a top-selling Alzheimer's drug in favor of a pricier extended-release version, a move that New York's attorney general has said would suppress generic competition. New York Attorney General Eric Schneiderman filed an antitrust lawsuit against Dublin- based Actavis...

  • *Netflix to raise share authorization in step to split stock. Shares of big pharmaceutical companies were among the biggest drags on the Dow and S&P 500, with Johnson& Johnson down 1.2 percent. Estimates for first-quarter S&P 500 results have fallen sharply since Jan. 1, with earnings for the period expected to have declined 2.9 percent from a year ago, Thomson...

  • CHICAGO, April 10- Sales of human antibiotics in the United States for use in livestock jumped by 20 percent between 2009 and 2013, federal regulators said on Friday, although recent statements by producers suggest those figures could be dropping. Companies such as Tyson Foods Inc and Perdue Farms have said in the past year, however, they have either reduced or...

  • U.S. meat industry buying more human antibiotics -FDA Friday, 10 Apr 2015 | 11:39 AM ET

    CHICAGO, April 10- Sales of medically important antibiotics in the United States for use in livestock jumped by 20 percent between 2009 and 2013, federal regulators reported on Friday, data that is sure to feed the national debate about the growth of drug-resistant bacteria. The U.S. Food and Drug Administration reported that domestic sales and distribution...

  • Drug name...or Star Wars planet?   Friday, 10 Apr 2015 | 9:30 AM ET
    Drug name...or Star Wars planet?

    Prescription drugs have weird names. But so do planets in the Star Wars universe. We asked CNBC staffers whether they could tell the difference.

  • Here's why drug names sound so weird   Friday, 10 Apr 2015 | 9:30 AM ET
    Here's why drug names sound so weird

    CNBC's Meg Tirrell and Eric Chemi break down why prescription drug names sound more like Star Trek planets than medication.

  • *FTSE 100 up 0.4 pct, in line with European region. LONDON, April 10- Top UK shares rose on Friday, nearing all-time highs as real-estate stocks extended gains from a rebound in property prices and drugmaker Shire got a lift from a priority drug review in the United States. The FTSE 100 rose 0.3 percent to 7,037.57 points, close to an all-time high of 7,065.08 points hit...

  • TOKYO, April 10- Japan's Nikkei share average topped the psychological 20,000- point mark on Friday for the first time in 15 years on hopes of stronger corporate earnings, and gained 2.4 percent on the week. Up until now, both camps were buying but from now some investors will be selling, "said Masayuki Doshida, senior market analyst at Rakuten Securities.

  • *Nikkei succumbs to profit-taking after hitting 20,000 mark. TOKYO, April 10- Japan's Nikkei share average slipped on Friday when the initial euphoria as it topped the psychological milestone of 20,000 was quickly taken over by selling to lock in the past few months' solid gains. Up until now, both camps were buying but from now some investors will be selling, "said...

  • The business of 3D bioprinting   Thursday, 9 Apr 2015 | 6:51 PM ET
    The business of 3D bioprinting

    Keith Murphy, chairman & CEO of Organovo, explains how 3D bioprinting technology works in this week's "Shake It Up" - a weekly series on CNBC's "The Rundown."

  • Controversial Alzheimer's drugmaker tactic   Thursday, 9 Apr 2015 | 5:22 PM ET
    Controversial Alzheimer's drugmaker tactic

    Actavis is headed to court in an effort to pull its Alzheimer drug from the market before its patent expires. Details, with CNBC's Meg Tirrell.

  • Japan's Eisai to cut about 450 jobs in U.S. Thursday, 9 Apr 2015 | 5:12 PM ET

    April 9- Japanese pharmaceutical company Eisai Co Ltd said it would cut about 25 percent, or about 450 jobs, in the United States as part of a realignment to create a more efficient and focused company. The company's U.S. unit Eisai Inc employs about 1,800 people in the United States, according to its website, across operations such as research and development,...